UK Inhalable Biologics Market Size & Outlook, 2025-2030
Related Markets
UK inhalable biologics market highlights
- The UK inhalable biologics market generated a revenue of USD 140.4 million in 2024 and is expected to reach USD 390.6 million by 2030.
- The UK market is expected to grow at a CAGR of 18.6% from 2025 to 2030.
- In terms of segment, peptides and proteins was the largest revenue generating type in 2024.
- RNAi-based Therapeutics is the most lucrative type segment registering the fastest growth during the forecast period.
Inhalable biologics market data book summary
| Market revenue in 2024 | USD 140.4 million |
| Market revenue in 2030 | USD 390.6 million |
| Growth rate | 18.6% (CAGR from 2025 to 2030) |
| Largest segment | Peptides and proteins |
| Fastest growing segment | RNAi-based Therapeutics |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Peptides and Proteins, Vaccines, Monoclonal Antibodies, RNAi-based Therapeutics |
| Key market players worldwide | Kamada, MannKind, Ab Initio, Ocugen, CanSino Biologics Inc Class H, AstraZeneca PLC |
Other key industry trends
- In terms of revenue, UK accounted for 3.7% of the global inhalable biologics market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany inhalable biologics market is projected to lead the regional market in terms of revenue in 2030.
- UK is the fastest growing regional market in Europe and is projected to reach USD 390.6 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Inhalable Biologics Market Scope
Inhalable Biologics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Ocugen | View profile | 51-100 | Malvern, Pennsylvania, United States, North America | http://ocugen.com |
| Ab Initio | View profile | 501-1000 | Lexington, Massachusetts, United States, North America | http://www.abinitio.com |
| MannKind | View profile | 501-1000 | Valencia, California, United States, North America | http://mannkindcorp.com |
| Kamada | View profile | 101-250 | Ness Ziona, HaMerkaz, Israel, Asia | http://kamada.com |
| AstraZeneca PLC | View profile | 89900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | https://www.astrazeneca.com |
| CanSino Biologics Inc Class H | View profile | 1494 | 185 South Avenue, 401-420, 4th Floor, Biomedical Park, TEDA West District, Tianjin, China, People's Republic of, | https://www.cansinotech.com |
UK inhalable biologics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to inhalable biologics market will help companies and investors design strategic landscapes.
Peptides and proteins was the largest segment with a revenue share of 35.33% in 2024. Horizon Databook has segmented the UK inhalable biologics market based on peptides and proteins, vaccines, monoclonal antibodies, rnai-based therapeutics covering the revenue growth of each sub-segment from 2018 to 2030.
The UK market is driven by increased funding for biopharmaceutical R&D and a focus on personalized medicine. Demand for inhalable biologics targeting asthma and COPD is rising, with expanding clinical trials and partnerships between academia and industry.
Retail pharmacies are gaining traction in chronic disease management, complementing hospital pharmacy distribution channels.
Reasons to subscribe to UK inhalable biologics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of UK inhalable biologics market databook
-
Our clientele includes a mix of inhalable biologics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the UK inhalable biologics market , including forecasts for subscribers. This country databook contains high-level insights into UK inhalable biologics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
UK inhalable biologics market size, by type, 2018-2030 (US$M)
UK Inhalable Biologics Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
